BACKGROUND: The traditional paradigm of glomerular filtration rate (GFR) progression in patients with chronic kidney disease (CKD) is a steady nearly linear decline over time. We describe individual GFR progression trajectories over 12 years of follow-up in participants in the African American Study of Kidney Disease and Hypertension (AASK). STUDY DESIGN: Longitudinal observational study. SETTING & PARTICIPANTS: 846 AASK patients with at least 3 years of follow-up and 8 GFR estimates. MEASUREMENTS: Longitudinal GFR estimates from creatinine-based equations. PREDICTORS: Patient demographic and clinical features. OUTCOMES: Probability of a nonlinear trajectory and probability of a period of nonprogression calculated for each patient from a Bayesian model of individual estimated GFR (eGFR) trajectories. RESULTS: 352 (41.6%) patients showed a > 0.9 probability of having either a nonlinear trajectory or a prolonged nonprogression period; in 559 (66.1%), the probability was > 0.5. Baseline eGFR > 40 mL/min/1.73 m2 and urine protein-creatinine ratio < 0.22 g/g were associated with a higher likelihood of a nonprogression period. 74 patients (8.7%) had both a substantial period of stable or increasing eGFR and a substantial period of rapid eGFR decrease. LIMITATIONS: Clinical trial population; absence of direct GFR measurements. CONCLUSIONS: In contrast to the traditional paradigm of steady GFR progression over time, many patients with CKD have a nonlinear GFR trajectory or a prolonged period of nonprogression. These findings highlight the possibility that stable kidney disease progression can accelerate and, conversely, provide hope that CKD need not be relentlessly progressive. These results should encourage researchers to identify time-dependent factors associated with periods of nonprogression and other desirable trajectories. Copyright Â
RCT Entities:
BACKGROUND: The traditional paradigm of glomerular filtration rate (GFR) progression in patients with chronic kidney disease (CKD) is a steady nearly linear decline over time. We describe individual GFR progression trajectories over 12 years of follow-up in participants in the African American Study of Kidney Disease and Hypertension (AASK). STUDY DESIGN: Longitudinal observational study. SETTING & PARTICIPANTS: 846 AASKpatients with at least 3 years of follow-up and 8 GFR estimates. MEASUREMENTS: Longitudinal GFR estimates from creatinine-based equations. PREDICTORS: Patient demographic and clinical features. OUTCOMES: Probability of a nonlinear trajectory and probability of a period of nonprogression calculated for each patient from a Bayesian model of individual estimated GFR (eGFR) trajectories. RESULTS: 352 (41.6%) patients showed a > 0.9 probability of having either a nonlinear trajectory or a prolonged nonprogression period; in 559 (66.1%), the probability was > 0.5. Baseline eGFR > 40 mL/min/1.73 m2 and urine protein-creatinine ratio < 0.22 g/g were associated with a higher likelihood of a nonprogression period. 74 patients (8.7%) had both a substantial period of stable or increasing eGFR and a substantial period of rapid eGFR decrease. LIMITATIONS: Clinical trial population; absence of direct GFR measurements. CONCLUSIONS: In contrast to the traditional paradigm of steady GFR progression over time, many patients with CKD have a nonlinear GFR trajectory or a prolonged period of nonprogression. These findings highlight the possibility that stable kidney disease progression can accelerate and, conversely, provide hope that CKD need not be relentlessly progressive. These results should encourage researchers to identify time-dependent factors associated with periods of nonprogression and other desirable trajectories. Copyright Â
Authors: E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245
Authors: Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: J Lewis; L Agodoa; D Cheek; T Greene; J Middleton; D O'Connor; A Ojo; R Phillips; M Sika; J Wright Journal: Am J Kidney Dis Date: 2001-10 Impact factor: 8.860
Authors: B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245
Authors: Keith C Norris; Tom Greene; Joel Kopple; Janice Lea; Julia Lewis; Mike Lipkowitz; Pete Miller; Annie Richardson; Stephen Rostand; Xuelei Wang; Lawrence J Appel Journal: J Am Soc Nephrol Date: 2006-09-07 Impact factor: 10.121
Authors: Jennifer J Gassman; Tom Greene; Jackson T Wright; Lawrence Agodoa; George Bakris; Gerald J Beck; Janice Douglas; Ken Jamerson; Julia Lewis; Michael Kutner; Otelio S Randall; Shin-Ru Wang Journal: J Am Soc Nephrol Date: 2003-07 Impact factor: 10.121
Authors: Lawrence J Appel; John Middleton; Edgar R Miller; Michael Lipkowitz; Keith Norris; Lawrence Y Agodoa; George Bakris; Janice G Douglas; Jeanne Charleston; Jennifer Gassman; Tom Greene; Kenneth Jamerson; John W Kusek; Julia A Lewis; Robert A Phillips; Stephen G Rostand; Jackson T Wright Journal: J Am Soc Nephrol Date: 2003-07 Impact factor: 10.121
Authors: Chi-Yuan Hsu; Raymond K Hsu; Kathleen D Liu; Jingrong Yang; Amanda Anderson; Jing Chen; Vernon M Chinchilli; Harold I Feldman; Amit X Garg; Lee Hamm; Jonathan Himmelfarb; James S Kaufman; John W Kusek; Chirag R Parikh; Ana C Ricardo; Sylvia E Rosas; Georges Saab; Daohang Sha; Edward D Siew; James Sondheimer; Jonathan J Taliercio; Wei Yang; Alan S Go Journal: J Am Soc Nephrol Date: 2019-06-24 Impact factor: 10.121
Authors: Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel Journal: N Engl J Med Date: 2013-11-09 Impact factor: 91.245
Authors: Godela M Brosnahan; Kaleab Z Abebe; Charity G Moore; Frederic F Rahbari-Oskoui; Kyongtae T Bae; Jared J Grantham; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Marie C Hogan; Ronald D Perrone; Dana C Miskulin; Theodore I Steinman; Vicente E Torres Journal: Am J Kidney Dis Date: 2018-01-03 Impact factor: 8.860
Authors: Carlos E Palant; Lakhmir S Chawla; Charles Faselis; Ping Li; Thomas L Pallone; Paul L Kimmel; Richard L Amdur Journal: Am J Physiol Renal Physiol Date: 2016-05-18